Weil is advising Remedy Meds, LLC in its definitive agreement to acquire Thirty Madison, Inc., which offers end-to-end, high-quality virtual specialized care for patients experiencing a range of conditions. The transaction is valued just north of $500 million and is an all-stock deal. The transaction is expected to close in Q4 2025 and is subject to customary closing conditions and regulatory review.

Remedy Meds is a consumer health platform that combines a performance-driven acquisition engine, a clinical retention system, and a national, integrated pharmacy care network to deliver affordable, convenient treatment for high-demand conditions.

The Weil team is led by U.S. Private Equity Co-Head Kyle Krpata and includes associates Liam Rozanski, Austin Peng, Coty Allen, and Logan Lowe; Banking & Finance partners Danek Freeman and Justina Chen and associates Solomon Leung and Ryan Miao; Tax partner Jason Vollbracht and associate Sarah Yue; Antitrust partner Jasmine Rosner, counsel Carla Hine, and associates Geneva Hardesty and Danielle Norgren; Technology & IP Transactions partner Max Scott and associate Jeeyoon Chung; Executive Compensation & Benefits partner Amanda Rotkel and associates Justine Park and Rustin Armknecht; Privacy partner Liza Cotter and associates David Merck, Taya Bokert and Kristen Pavlounis; and Employment partner Rebecca Sivitz and associate Zeinab Bakillah.